Blue background

Pipeline and Clinical Trials

Endocrine & Metabolic

Compound
Target Indication
Phase I
Phase II
Phase III
Compound
Target Indication
Cushing syndrome
Currently in Phase Three
Compound
CORT118335
Target Indication
NASH
Phase One Completed
Target Indication
Antipsychotic-induced weight gain
Phase One Completed

Oncology

Compound
Target Indication
Phase I
Phase II
Phase III
Target Indication
Pancreatic cancer
Phase Two
Target Indication
Ovarian cancer
Phase Two
Target Indication
Castration-resistant prostate cancer
Phase Two
Target Indication
Castration-resistant prostate cancer
Phase Two
Target Indication
Metastatic GR-positive triple-negative breast cancer
Phase Two
Target Indication
Metastatic HER2-negative breast cancer
Phase Two

Addiction

Compound
Target Indication
Phase I
Phase II
Phase III
Target Indication
Alcohol use disorder
Phase Two
Compound
Target Indication
Nicotine use disorder
Phase One

Ophthalmology

Compound
Target Indication
Phase I
Phase II
Phase III
Compound

Additional Areas of Research

Alzheimer’s disease
Anxiety
Diabetes
Hypertension
Neurodegenerative diseases
Nonsmall cell lung cancer
Obesity
Osteoporosis
Posttraumatic stress disorder

 

GR, glucocorticoid receptor; HER2, human epidermal growth factor receptor 2; Nab-paclitaxel, nanoparticle albumin-bound paclitaxel; NASH, nonalcoholic steatohepatitis.

1Study sponsored by University of Chicago.
2Study sponsored by University of Chicago and the National Cancer Institute.
3Study sponsored by the Scripps Research Institute and the National Institute on Alcohol Abuse and Alcoholism.

4Study sponsored by Yale University.
5Study sponsored by Bay Area Retina Associates and Ophthalmic Consultants of Boston.

Corcept's Clinical Trials

View Information on Clinical Trials

Clinical Trials